Medexus Pharmaceuticals Inc. (TSE:MDP) Given Average Rating of "Buy" by Brokerages

Key Points

• Medexus Pharmaceuticals Inc. has received a consensus rating of "Buy" from seven rating firms, with four analysts issuing a strong buy rating and the average 1-year price target set at C$5.49.
• The company's stock has seen a 4.2% increase recently, with shares currently priced at C$2.75, and it has a market capitalization of C$61.57 million.
• Medexus Pharmaceuticals specializes in products for auto-immune disease and pediatrics, including treatments like Rasuvo and Metoject for rheumatoid arthritis.

Shares of Medexus Pharmaceuticals Inc. (TSE:MDP - Get Free Report) have been given a consensus rating of "Buy" by the seven ratings firms that are covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a hold rating, one has given a buy rating and four have given a strong buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is C$5.49.

Separately, Alliance Global Partners upgraded Medexus Pharmaceuticals to a "strong-buy" rating in a report on Monday.

Medexus Pharmaceuticals Stock Up 4.2%

Shares of MDP opened at C$2.75 on Wednesday. Medexus Pharmaceuticals has a twelve month low of C$1.71 and a twelve month high of C$5.56. The company has a 50 day moving average of C$2.93 and a 200-day moving average of C$2.83. The stock has a market capitalization of C$61.57 million, a P/E ratio of 13.15 and a beta of 1.96.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc, formerly Pediapharm Inc is a leading specialty pharmaceutical company with a strong North American commercial platform. It is focused on the therapeutic areas of auto-immune disease and pediatrics. The leading products are Rasuvo and Metoject, a unique formulation of methotrexate to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an innovative allergy medication with a unique mode of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.